Puhr, Hannah Christina
Karner, Alexander
Taghizadeh, Hossein
Jomrich, Gerd
Schoppmann, Sebastian Friedrich
Preusser, Matthias
Ilhan-Mutlu, Aysegül http://orcid.org/0000-0001-8291-0873
Funding for this research was provided by:
Medizinische Universität Wien
Article History
Received: 23 April 2020
Accepted: 24 June 2020
First Online: 2 July 2020
Compliance with ethical standards
:
: HC.P. has received travel support from Eli Lilly, MSD, Novartis, Pfizer and Roche. AS.B. has research support from Daiichi Sankyo and Roche, honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen, Daiichi Sankyo and AbbVie. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Merck Sharp & Dome. A.I-M. participated in advisory boards from MSD and Servier, received lecture honoraria from Eli Lilly and Servier, is the local PI for clinical trials sponsored by BMS and Astellas. Other authors have nothing to declare.
: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. Due to the retrospective design, no separate informed consent was necessary in the scope of this study. The study was approved by the ethics committee of the Medical University of Vienna (signee Jürgen Zezula, reference number: 2267/2016).
: The data that support the findings of this study are available from the corresponding author, A.I-M., upon reasonable request.